Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Arecor is awarded key patents in the EU and China protecting the novel formulations of its proprietary Arestat insulin products, AT278 and AT247. The European Patent Office awards patent EP3518892, while China National Intellectual Property Administration grants patent CN110582285. Firm's patent portfolio now comprises 36 patent families, with over 75 granted patents in Europe, the US and other key territories.
"These additional granted patents aim to serve and protect Arecor's innovative technologies in these important markets," says Chief Scientific Officer Jan Jezek.
Current stock price: 230.66 pence, down 3.9% on Tuesday
12-month change: down 34%
By Elizabeth Winter, Alliance News senior markets reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.